DT-7012

Phase 1Small molecule

DDomain Therapeutics Australia Pty Ltd

DT-7012 is one of 51 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous T-Cell LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Cutaneous T-Cell Lymphoma

#DrugCompanyPhaseTrials

Adcetris

Pfizer

Phase 3

4 2

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 3

Poteligeo

KKyowa Kirin, Inc.

Phase 3

2 4

Istodax

Teva

Phase 2

5 5

Keytruda

Merck & Co.

Phase 2

2 6

Arranon

Novartis

Phase 2

1 7

Afinitor

Novartis

Phase 2

1 8

Fludara

Sanofi

Phase 2

1 9

Libtayo

Regeneron

Phase 2

1 10

Humax-CD4

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Immune Checkpoint Inhibitor

NCT06819735

Q3 2028

Phase 1Not yet recruiting

Cutaneous T-Cell Lymphoma

NCT07213882

Clinical

Trials by Indication[1]

Immune Checkpoint Inhibitor1 trial

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Recruiting·DDomain Therapeutics Australia Pty Ltd·Phase 1/2·NCT06819735·125 enrolled

Cutaneous T-cell lymphoma1 trial

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07213882·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DT-7012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DT-7012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DT-7012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Domain Therapeutics Australia Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDomain Therapeutics Australia Pty Ltd

DT-7012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Immune Checkpoint Inhibitor1 trial

Cutaneous T-cell lymphoma1 trial

References

Drug Info

Quick Facts

Related News